3水平与慢性心力衰竭患者预后关系的Meta分析

发布时间：2016-10-16 16:12

  本文关键词：血清半乳糖凝集素-3水平与慢性心力衰竭患者预后关系的Meta分析，由笔耕文化传播整理发布。

循证医学

血清半乳糖凝集素-3水平与慢性心力衰竭患者预后关系的Meta分析 周恒, 唐其柱， 代佳 ，袁园， 石宏伟

430060 武汉大学人民医院心内科 武汉大学心血管病研究所
唐其柱，Email: qztang@whu.edu.cn

摘要:目的 评价血清半乳糖凝集素-3(galectin-3)水平与慢性心力衰竭(chronic heart failure，CHF)患者预后之间的关系。方法 检索Pubmed、Embase、Cochrane图书馆、中国生物医学文献数据库、中国知网、万方等数据库，筛选关于半乳糖凝集素-3与CHF预后关系的中英文文献，提取风险比(hazard ratio，HR)及其95%可信区间(confidence interval，CI)。对纳入的文献进行质量评价，采用STATA 12.0软件进行Meta分析。结果 纳入6篇符合要求的文献，异质性检验表明研究具有异质性，随机效应模型合并统计量显示在未排除其他影响因素的情况下，半乳糖凝集素-3预测CHF的HR=1.63，95% CI 1.26～2.11;排除其他影响因素后，，HR=1.23，95% CI 1.07～1.42。结论 高水平半乳糖凝集素-3可能是CHF不良预后的独立危险因素。

关键词:半乳糖凝集素-3; 心力衰竭; 预后; Meta分析; 全因死亡率

国家自然科学基金（81300070，81270303）

Prognostic significance of serum galectin-3 level in chronic heart failure: a Meta analysis ZHOU Heng, TANG Qi-zhu, DAI Jia, YUAN Yuan, SHI Hong-wei

Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan University, Wuhan 430060, China
TANG Qi-zhu, Email: qztang@whu.edu.cn

Abstract:Objective To evaluate the relation between serum galectin-3 level and chronic heart failure (CHF) prognosis. Methods Articles which involved relation between galectin-3 and CHF prognosis were searched in Pubmed, Embase, Cochrane Library, Chinese Biomedical Literature Database, CNKI and WANFANG Databases. Hazard ratio (HR) and 95% confidence interval (CI) in each literature were extracted for meta-analysis using STATA 12.0 software. Results Six literature complying with the requirements were included. Heterogeneity test showed that heterogeneity exists in different studies, and statistics were combined using a random effects model. Under the influence of other factors, the combined HR was 1.63 and 95% CI was 1.26-2.11. When the influence of other factors were excluded, the combined HR was 1.23 and 95% CI was 1.07-1.42. Conclusion High serum level of galectin-3 may be an independent risk factor for poor prognosis of CHF patients.

Keywords:Galectin 3; Heart failure; Prognosis; Meta-analysis; All cause mortality

字体

阅读

PDF (1.2MB)

评论

参考文献 　　[1] Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet, 2011, 378: 704-712.

　　[2] Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol, 2011, 8: 30-41.

　　[3] Gonzalez A, Ravassa S, Beaumont J, et al. New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol, 2011, 58: 1833-1843.

　　[4] Karayannis G, Triposkiadis F, Skoularigis J, et al. The Emerging Role of Galectin-3 and ST2 in Heart Failure: Practical Considerations and Pitfalls Using Novel Biomarkers. Curr Heart Fail Rep, 2013, 10: 441-449.

　　[5] Hrynchyshyn N, Jourdain P, Desnos M, et al. Galectin-3: A new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure. Arch Cardiovasc Dis, 2013, 106: 541-546.

　　[6] Chen K, Jiang RJ, Wang CQ, et al. Predictive value of plasma galectin-3 in patients with chronic heart failure. Eur Rev Med Pharmacol Sci, 2013, 17: 1005-1011.

　　[7] Tang WH, Shrestha K, Shao Z, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol, 2011, 108: 385-390.

　　[8] Lok DJ, Klip IT, Lok SI, et al. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am J Cardiol, 2013, 112: 831-837.

　　[9] Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol, 2010, 99: 323-328.

　　[10] de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med, 2011, 43: 60-68.

　　[11] Ueland T, Aukrust P, Broch K, et al. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int J Cardiol, 2011, 150: 361-364.

　　[12] Felker GM, Fiuzat M, Shaw LK, et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail, 2012, 5: 72-78.

　　[13] Gullestad L, Ueland T, Kjekshus J, et al. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J, 2012, 164: 878-883.

　　[14] Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation, 2004, 110: 3121-3128.

　　[15] Yu L, Ruifrok WP, Meissner M, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail, 2013, 6: 107-117.
(编辑：戚红丹 收稿日期：2013-11-18)

  本文关键词：血清半乳糖凝集素-3水平与慢性心力衰竭患者预后关系的Meta分析，由笔耕文化传播整理发布。

本文编号：141918